bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors: Xochelli Aliki , Baliakas Panagiotis , Kavakiotis Ioannis , Agathangelidis Andreas , Sutton Lesley-Ann , Minga Eva , Ntoufa Stavroula , Tausch Eugen , Yan Xiao-Jie , Shanafelt Tait , Plevova Karla , Boudjogra Myriam , Rossi Davide , Davis Zadie , Navarro Alba , Sandberg Yorick , Vojdeman Fie Juhl , Scarfo Lydia , Stavroyianni Niki , Sudarikov Andrey , Veronese Silvio , Tzenou Tatiana , Karan-Djurasevic Teodora , Catherwood Mark , Kienle Dirk , Chatzouli Maria , Facco Monica , Bahlo Jasmin , Pott Christiane , Pedersen Lone Bredo , Mansouri Larry , Smedby Karin E. , Chu Charles C. , Giudicelli Véronique , Lefranc Marie-Paule , Panagiotidis Panagiotis , Juliusson Gunnar , Anagnostopoulos Achilles , Vlahavas Ioannis , Antic Darko , Trentin Livio , Montillo Marco , Niemann Carsten , Döhner Hartmut , Langerak Anton W. , Pospisilova Sarka , Hallek Michael , Campo Elias , Chiorazzi Nicholas , Maglaveras Nikos , Oscier David , Gaidano Gianluca , Jelinek Diane F. , Stilgenbauer Stephan , Chouvarda Ioanna , Darzentas Nikos , Belessi Chrysoula , Davi Frederic , Hadzidimitriou Anastasia , Rosenquist Richard , Ghia Paolo , Stamatopoulos Kostas
Published: April 2023

Univariable and multivariable analysis for TTFT within M-CLL.
Figure S3A from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors: Xochelli Aliki , Baliakas Panagiotis , Kavakiotis Ioannis , Agathangelidis Andreas , Sutton Lesley-Ann , Minga Eva , Ntoufa Stavroula , Tausch Eugen , Yan Xiao-Jie , Shanafelt Tait , Plevova Karla , Boudjogra Myriam , Rossi Davide , Davis Zadie , Navarro Alba , Sandberg Yorick , Vojdeman Fie Juhl , Scarfo Lydia , Stavroyianni Niki , Sudarikov Andrey , Veronese Silvio , Tzenou Tatiana , Karan-Djurasevic Teodora , Catherwood Mark , Kienle Dirk , Chatzouli Maria , Facco Monica , Bahlo Jasmin , Pott Christiane , Pedersen Lone Bredo , Mansouri Larry , Smedby Karin E. , Chu Charles C. , Giudicelli Véronique , Lefranc Marie-Paule , Panagiotidis Panagiotis , Juliusson Gunnar , Anagnostopoulos Achilles , Vlahavas Ioannis , Antic Darko , Trentin Livio , Montillo Marco , Niemann Carsten , Döhner Hartmut , Langerak Anton W. , Pospisilova Sarka , Hallek Michael , Campo Elias , Chiorazzi Nicholas , Maglaveras Nikos , Oscier David , Gaidano Gianluca , Jelinek Diane F. , Stilgenbauer Stephan , Chouvarda Ioanna , Darzentas Nikos , Belessi Chrysoula , Davi Frederic , Hadzidimitriou Anastasia , Rosenquist Richard , Ghia Paolo , Stamatopoulos Kostas
Published: April 2023

CLL with mutated IGHV4-34 receptors: shared and distinct clinical outcomes. A. IgG subsets #4 and #16 displayed significantly (p=0.023) longer TTFT compared to non-subset IGHV4-34 M-CLL cases.
Supplementary Table 1 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Comparison of gene expression between the NPC derived glioma cells M7, GL26 and GL26A1 cells (Affymetrix Gene Chip Data).
Supplementary Figure 5 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Analysis of tumor area in brains from animals treated for 5 days with either saline or AMD3100.
Supplemental Table 1 from Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Authors: Hu Yuebi , Alden Ryan S. , Odegaard Justin I. , Fairclough Stephen R. , Chen Ruthia , Heng Jennifer , Feeney Nora , Nagy Rebecca J. , Shah Jayshree , Ulrich Bryan , Gutierrez Martin , Lanman Richard B. , Garber Judy E. , Paweletz Cloud P. , Oxnard Geoffrey R.
Published: April 2023

Alterations detectable by Guardant360 gene panel
Supplementary Table S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Authors: Gray Jhanelle E. , Heist Rebecca S. , Starodub Alexander N. , Camidge D. Ross , Kio Ebenezer A. , Masters Gregory A. , Purcell W. Thomas , Guarino Michael J. , Misleh Jamal , Schneider Charles J. , Schneider Bryan J. , Ocean Allyson , Johnson Tirrell , Gandhi Leena , Kalinsky Kevin , Scheff Ronald , Messersmith Wells A. , Govindan Serengulam V. , Maliakal Pius P. , Mudenda Boyd , Wegener William A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Supplementary Figure 3A from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Kaplan-Meier (A) estimated overall survival (OS)
Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Major molecular response by 12 months, by Sokal risk group. bid, twice daily; MMR, major molecular response (defined as BCR-ABL1 transcript level {less than or equal to}0.1% [MR3.0]); qd, daily.
Supplementary Figure 1D from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (d) Radotinib 400 mg bid (n = 79 patients with evaluable molecular data at 3 months).
Supplementary Figure 1 from Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non–Small Cell Lung Cancer Cell Lines and Tumor Models
Authors: Dadey David Y.A. , Kapoor Vaishali , Hoye Kelly , Khudanyan Arpine , Collins Andrea , Thotala Dinesh , Hallahan Dennis E.
Published: April 2023

Treatment with antibody against GRP78 does not reduce proliferation and colony formation in normal cell lines.
Supplementary Figure S2 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

FGFR1 expression in cancer cell lines.
Supplemental Figure 5 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

A. Western blot of Hif-1a and Hif-2a in ccRCC cell lines. B. Relative mRNA expression levels of HIF-target genes upon transaction with siHif-1a and/or siHIF-2a
Table S2 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Primary HPCa samples used in this study
Supplementary Table 4 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

miRNA Expression Data
S1: MPX Manufacturing Process and Chemical Constituents from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Paller Channing J. , Zhou Xian C. , Heath Elisabeth I. , Taplin Mary-Ellen , Mayer Tina , Stein Mark N. , Bubley Glenn J. , Pili Roberto , Hudson Tamaro , Kakarla Radhika , Abbas Muneer M. , Anders Nicole M. , Dowling Donna , King Serina , Bruns Ashley B. , Wagner William D. , Drake Charles G. , Antonarakis Emmanuel S. , Eisenberger Mario A. , Denmeade Samuel R. , Rudek Michelle A. , Rosner Gary L. , Carducci Michael A.
Published: April 2023

S1 describes the process employed in manufacturing MPX and summarizes the chemical constituents of the MPX batch used in this study.
Fig. S6 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

TM+ HPCa cells are more castration-resistant in vitro.
Supplementary figure 4 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

Combination of the mTORC1/2 inhibitor TAK-228 and the PI3K-α inhibitor alpelisib inhibits EMC041 tumor growth to the same extent as BEZ235
Supplementary figure 3 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

High-grade endometrial stromal sarcoma with YMHAE/NUTM2A/B fusion and cyclin D1 expression.
Fig. S4 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

AI tumors are less differentiated
Supplementary figure 1 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

Survival of uterine sarcoma patients according to tumor grade and histologic subtype.
Fig. S1 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Flow scheme
supplementary table 1 from Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study
Authors: Jiang Ni , Qiao Guoliang , Wang Xiaoli , Morse Michael A. , Gwin William R. , Zhou Lei , Song Yuguang , Zhao Yanjie , Chen Feng , Zhou Xinna , Huang Lefu , Hobeika Amy , Yi Xin , Xia Xuefeng , Guan Yanfang , Song Jin , Ren Jun , Lyerly H. Kim
Published: April 2023

Copy number variants (CNVs) in plasma samples
Supplementary Figure 2 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Supplementary Figure 2 - Patient characteristics in 6 cohorts analysed
Figure S1 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Kaplan-Meier curves showing lung cancer-specific survival in AAs and EAs in the mRNA and miRNA cohorts.
Table S3 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

Differentially expressed genes in sclerosing epithelioid fibrosarcoma (SEF) compared to control tumors and low-grade fibromyxoid sarcoma (LGFMS)
Supplemental Table 2 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Table 2 shows univariate and multivariate Cox regression analyses of overall 15-year and post-5-year prognostic performance of BCIN+.
Kaplan-Meier analysis of progression free survival of all patients with ATL who received alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
Authors: Sharma Kamal , Janik John E. , O'Mahony Deirdre , Stewart Donn , Pittaluga Stefania , Stetler-Stevenson Maryalice , Jaffe Elaine S. , Raffeld Mark , Fleisher Thomas A. , Lee Cathryn C. , Steinberg Seth M. , Waldmann Thomas A. , Morris John C.
Published: April 2023

Kaplan-Meier analysis of progression free survival of all patients with ATL who received alemtuzumab therapy
Supplemental Figure 5 from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

In vitro characterization of the KLN205 cell line to reovirus, sunitinib and combination therapy.
Supplementary Material CCR-16-2392 from Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL
Authors: Jones Luke , Richmond Jennifer , Evans Kathryn , Carol Hernan , Jing Duohui , Kurmasheva Raushan T. , Billups Catherine A. , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Figure S1. Current scoring method for preclinical testing of novel agents. Supplementary Figure S2. Correlations between log10 fold change and LGD or TT1%, and %huCD45+ cells in PB with LGD. Supplementary Figure S3. Determination of tumor volume doubling time (TVDT) and log cell kill equivalent (LCKe) values. Supplementary Figure S4. Comparison of engraftment rates between transduced and nontransduced PDXs. Supplementary Figure S5. Comparison of gene expression profiles between transduced and non-transduced PDXs. Supplementary Table S1. Efficacy of VXL and venetoclax against ALL-11 and ALL-57 as measured by PB monitoring. Supplementary Table S2. Log10 fold change data in response to treatment as measured by BLI for the whole animal, as well as individual sites of leukemic engraftment. Supplementary Table S3. Log cell kill equivalent (LCKe) values for all treatment groups.
Suppl Table S2 from Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Authors: Kelly Kevin , Mejia Alex , Suhasini Avvaru N. , Lin An-Ping , Kuhn John , Karnad Anand B. , Weitman Steven , Aguiar Ricardo C.T.
Published: April 2023

Steady-state trough levels of roflumilast and its active metabolite N-oxide.
Supplemental Table 1 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Raje Noopur S. , Faber Edward A. , Richardson Paul G. , Schiller Gary , Hohl Raymond J. , Cohen Adam D. , Forero Andres , Carpenter Susan , Nguyen Tuan S. , Conti Ilaria , Kaiser Christopher J. , Cronier Damien M. , Wooldridge James E. , Anderson Kenneth C.
Published: April 2023

Pharmacokinetic parameters of tabalumab in multiple myeloma patients
Supplemental Figure from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Raje Noopur S. , Faber Edward A. , Richardson Paul G. , Schiller Gary , Hohl Raymond J. , Cohen Adam D. , Forero Andres , Carpenter Susan , Nguyen Tuan S. , Conti Ilaria , Kaiser Christopher J. , Cronier Damien M. , Wooldridge James E. , Anderson Kenneth C.
Published: April 2023

Percentage Change from Baseline (PCB) for B-cells (CD19+) and Immunoglobulins (Ig)at 20-day time intervals post-baseline.
Supple Figs. S1-S4 from RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer
Authors: Wang Yifan , Gudikote Jayanthi , Giri Uma , Yan Jun , Deng Weiye , Ye Rui , Jiang Wen , Li Nan , Hobbs Brian P. , Wang Jing , Swisher Stephen G. , Fujimoto Junya , Wistuba Ignacio I. , Komaki Ritsuko , Heymach John V. , Lin Steven H.
Published: April 2023

Supplementary Figure S1. Q-Q plot of NSCLC cell line radiosensitivity distribution. Supplementary Figure S2. Kaplan-Meier curve of in-field recurrence free survival in high-RAD50 and low-RAD50 tumors in all patients (Suppl. Fig. S2A) and in stage III patients (Suppl. Fig. S2B). Supplementary Figure S3. Column graph of RAD50 H-score in patients with or without neoadjuvant chemotherapy. Supplementary Figure S4. Cell cycle distribution of H23-SAM-RAD50 and H23-SAM-Control cells, with or without radiation.
Supplementary Materials from High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype
Authors: Dennison Jennifer B. , Shahmoradgoli Maria , Liu Wenbin , Ju Zhenlin , Meric-Bernstam Funda , Perou Charles M. , Sahin Aysegul A. , Welm Alana , Oesterreich Steffi , Sikora Matthew J. , Brown Robert E. , Mills Gordon B.
Published: April 2023

Statistical methods for RPPA; Supplemental references; Supplemental Figure S1: RPPA heatmap of TCGA cohort; Supplemental Figure S2: Diagram of RPPA proteins differentially expressed in Cluster II; Supplemental Figure S3: Expression of caveolin-1 by IHC in IDC; Supplemental Figure S4: Expression of E-cadherin by IHC in IDC; Supplemental Figure S5: Expression of RBM15 by IHC in IDC; Supplemental Figure S6: Association of RPPA subtypes with mRNA of selected genes; Supplemental Figure S7: Heatmap of RPPA protein expression of ER-pos breast cancer cell lines (IDC and ILC) and normal breast tissue; Supplemental Figure S8: Waterfall plots of RPPA proteins marked cancer or stroma derived in Reactive breast cancer (Cluster II); Supplemental Figure S9: Percent stroma as determined by compartment areas and cell counts; Supplemental Figure S10: Subtyping of MDACC ER-positive/HER2-negative breast cancers by RPPA; Supplemental Figure S11: Imaging summary for cell density and α-SMA scoring of TCGA cases; Supplemental Figure S12: Expression of α-SMA by IHC in ILC; Supplemental Figure S13: Expression of α-SMA by IHC of IDC; Supplemental Figure S14: Tumor purity, stromal scoring, EMT scoring, and immune scoring of RPPA subtypes; Supplemental Figure S15: Components of Nottingham grade for IDC; Supplemental Figure S16: RPPA heatmap of cases with matched normal tissues; Supplemental Table S1: The coefficient estimates of the final model using the core TCGA samples; Supplemental Table S2: The sensitivity, specificity and false discovery rate (FDR) from the test data sets using the final models from Table S1
Figure S1 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development
Authors: Jaworski Felipe M. , Gentilini Lucas D. , Gueron Geraldine , Meiss Roberto P. , Ortiz Emiliano G. , Berguer Paula M. , Ahmed Asif , Navone Nora , Rabinovich Gabriel A. , Compagno Daniel , Laderach Diego J. , Vazquez Elba S.
Published: April 2023

In vitro tubulogenesis assay. A, in vitro tube formation using control or hemin-treated HUVEC in the absence or presence of T-C1 conditioned media. Complete growth media served as a positive control. Figure depicts one representative out of three independent experiments. B, total tube length was quantified. *** indicates P<0.001
Supplementary table s4 from Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers
Authors: Hata Tatsuo , Dal Molin Marco , Hong Seung-Mo , Tamura Koji , Suenaga Masaya , Yu Jun , Sedogawa Hiraku , Weiss Matthew J. , Wolfgang Christopher L. , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael G.
Published: April 2023

Supplementary Table S4. Combination analysis of preoperative EUS-FNA cytology with methylated markers using 47 cases who underwent preoperative EUS.
Supplementary table s2 from Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers
Authors: Hata Tatsuo , Dal Molin Marco , Hong Seung-Mo , Tamura Koji , Suenaga Masaya , Yu Jun , Sedogawa Hiraku , Weiss Matthew J. , Wolfgang Christopher L. , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael G.
Published: April 2023

Supplementary Table S2. Characteristics of the discovery and validation sets.
Supplemental Figure 4 from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Authors: Lok Benjamin H. , Gardner Eric E. , Schneeberger Valentina E. , Ni Andy , Desmeules Patrice , Rekhtman Natasha , de Stanchina Elisa , Teicher Beverly A. , Riaz Nadeem , Powell Simon N. , Poirier John T. , Rudin Charles M.
Published: April 2023

Animal weights from dose finding toxicity study of talazoparib and temozolomide; and SLFN11 protein expression in patient-derived xenografts.
Supplementary Table 1 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Yuan Jianda , Postow Michael A. , Wong Phillip , Capone Mariaelena , Madonna Gabriele , Khammari Amir , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Martus Peter , Dreno Brigitte , Ascierto Paolo A. , Wolchok Jedd D. , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Antibody panels used for flow cytometry* FoxP3 buffer (BD) was used to fix and permeabilize cells. Only frequencies of frequencies of CD4+, CD8+ T cells from Treg panel 1 and, CD14+ cells from MDSC panel 1 were included. 1 Panel 1 (n=14), 2 Panel 2 (n=68).
Supplementary Figure 5 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Yuan Jianda , Postow Michael A. , Wong Phillip , Capone Mariaelena , Madonna Gabriele , Khammari Amir , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Martus Peter , Dreno Brigitte , Ascierto Paolo A. , Wolchok Jedd D. , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Overall survival according to clinical response and biomarker signature 12 weeks after start of ipilimumab. Overall survival (OS) was calculated from week 12 (day 84) to the date of last follow-up or death. OS according to clinical response in the week 12 tumor assessment (A) and according to the number of increasing cell subsets considering early changes in ALC, delayed changes in CD4+ T cells and delayed changes in CD8+ T cells (B). Among patients with clinical benefit (CR, PR, SD) in the 12 weeks tumor assessment those with increases in all three cell subsets had an excellent outcome. In contrast, three patients with early decrease in ALC and/or decrease of CD4+ or CD8+ frequencies had a poor prognosis despite of clinical benefit (C).
Supplemental Data from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Authors: Lok Benjamin H. , Gardner Eric E. , Schneeberger Valentina E. , Ni Andy , Desmeules Patrice , Rekhtman Natasha , de Stanchina Elisa , Teicher Beverly A. , Riaz Nadeem , Powell Simon N. , Poirier John T. , Rudin Charles M.
Published: April 2023

Supplemental Figure Legends and Supplemental Tables; Supplemental Table 1: Homologous recombination deficiency genomic scar assay scores in SCLC cell lines; Supplemental Table 2: Top gene hits that correlate with PARP inhibitor sensitivity; Supplemental Table 3. Random effect models testing if the treatment effect depends on SLFN11 expression level
Supplementary Figure Legends from Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway
Authors: Mei Qian , Li Xiang , Zhang Kang , Wu Zhiqiang , Li Xiaolei , Meng Yuanguang , Guo Mingzhou , Luo Guangbin , Fu Xiaobing , Han Weidong
Published: April 2023

Figure S1. Expression Levels of miRNAs within the Chromosomal Instability Site chr9q33.3 Figure S2. miR-181a/181b function as tumor suppressors in cervical cancer in vitro Figure S3. miR-181a2/181b2 did not exhibit significant effect on migration, invasion, and EMT of cervical cancer cells Figure S4. miR-181a2/b2 regulates PI3K/Akt/FoxO signal transduction in cervical cancer cells Figure S5. The relationship between miR-181a2/181b2, p-Akt, p-FoxO1 and p- JNK levels
Figure S2 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Authors: Pham Lan V. , Huang Shengjian , Zhang Hui , Zhang Jun , Bell Taylor , Zhou Shouhao , Pogue Elizabeth , Ding Zhiyong , Lam Laura , Westin Jason , Davis R. Eric , Young Ken H. , Medeiros L. Jeffrey , Ford Richard J. , Nomie Krystle , Zhang Leo , Wang Michael
Published: April 2023

Cell viability assays were performed using the Celltiter-Glo Luminescent Cell Viability Assay in representative MCL primary cells (PT-2 and PT-6) treated with increasing concentrations of ibrutinib (A) or idelalisib (B).
Supplementary Data from Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis
Authors: Hu Li-Peng , Zhang Xiao-Xin , Jiang Shu-Heng , Tao Ling-Ye , Li Qing , Zhu Li-Li , Yang Ming-Wei , Huo Yan-Miao , Jiang Yong-Sheng , Tian Guang-Ang , Cao Xiao-Yan , Zhang Yan-Li , Yang Qin , Yang Xiao-Mei , Wang Ya-Hui , Li Jun , Xiao Gary Guishan , Sun Yong-Wei , Zhang Zhi-Gang
Published: April 2023

Supplementary methods
List of Supplementary Tables from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

List of Supplementary Tables
Figure S3 from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Changes in ctDNA levels after local or systemic interventions such as surgery or chemotherapy divided into response and non-response groups.
Supplemental Figure 3B from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

Relationship between veliparib exposure-% CFB in PAR levels in PBMC (A) and �B in PAR levels-ORR (B)
Figure S2 from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Comparison of the time to relapse detection using CEA and standard-of-care CT imaging for fourteen relapse patients.
Supplementary Figures from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer
Authors: Kuroiwa-Trzmielina Joice , Wang Fan , Rapkins Robert W. , Ward Robyn L. , Buchanan Daniel D. , Win Aung Ko , Clendenning Mark , Rosty Christophe , Southey Melissa C. , Winship Ingrid M. , Hopper John L. , Jenkins Mark A. , Olivier Jake , Hawkins Nicholas J. , Hitchins Megan P.
Published: April 2023

Supplementary Figure 1. Allele quantification assays used to measure relative levels of mRNA expression at exonic SNPs within MGMT. Supplementary Figure 2. Allelic expression ratios of MGMT transcripts in the normal colorectal mucosa (NCM) of colorectal cancer (CRC) patients as measured by allele quantification (AQ) pyrosequencing at exon 3 SNP rs1803965.
Suppl Fig. 3 from Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Authors: Kenny Timothy C. , Schmidt Hank , Adelson Kerin , Hoshida Yujin , Koh Anna P. , Shah Nagma , Mandeli John , Ting Jess , Germain Doris
Published: April 2023

Supplementary Figure 3: Comparison of CLIC4 and RYBP mRNA levels in high score and low score treated MDA-MB-231 cells to untreated MDA-MB-231 cells. Real-time PCR of CLIC4 in untreated and high score treated MDA-MB-231 cells normalized to actin. (Mean {plus minus} SEM) (in quadruplicate, ** p < 0.01, Mann-Whitney test). Real-time PCR of RYBP in untreated and low score treated MDA-MB-231 cells normalized to actin. (Mean {plus minus} SEM) (in quadruplicate, ** p < 0.01, Mann-Whitney test).
Suppl Fig. 2 from Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Authors: Kenny Timothy C. , Schmidt Hank , Adelson Kerin , Hoshida Yujin , Koh Anna P. , Shah Nagma , Mandeli John , Ting Jess , Germain Doris
Published: April 2023

Supplementary Figure 2: Low score PSF does not suppress proliferation. Proliferation curve ofMDA-MB-231 cells treated with 1% Low Score PSF, 1% High Score PSF, or 1% FBS using an MTT assay. (Mean {plus minus} SEM) (n = 5 per group; * p < 0.05; Mann-Whitney test)
Supplemental Table 1 from Underreporting of Research Biopsies from Clinical Trials in Oncology
Authors: Parseghian Christine M. , Raghav Kanwal , Wolff Robert A. , Ensor Joe , Yao James , Ellis Lee M. , Tam Alda L. , Overman Michael J.
Published: April 2023

Characteristics and Reporting by Trial
supplementary notes from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
Authors: Gulati Pratiksha , Rühl Julia , Kannan Abhilash , Pircher Magdalena , Schuberth Petra , Nytko Katarzyna J. , Pruschy Martin , Sulser Simon , Haefner Mark , Jensen Shawn , Soltermann Alex , Jungraithmayr Wolfgang , Eisenring Maya , Winder Thomas , Samaras Panagiotis , Tabor Annett , Stenger Rene , Stupp Roger , Weder Walter , Renner Christoph , Münz Christian , Petrausch Ulf
Published: April 2023

Supplementary Materials and Methods, References
Table S1 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
Authors: Gulati Pratiksha , Rühl Julia , Kannan Abhilash , Pircher Magdalena , Schuberth Petra , Nytko Katarzyna J. , Pruschy Martin , Sulser Simon , Haefner Mark , Jensen Shawn , Soltermann Alex , Jungraithmayr Wolfgang , Eisenring Maya , Winder Thomas , Samaras Panagiotis , Tabor Annett , Stenger Rene , Stupp Roger , Weder Walter , Renner Christoph , Münz Christian , Petrausch Ulf
Published: April 2023

List of differentially regulated cell cycle genes with Log2FC values.
Supplemental figure 2 from Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Authors: Bannon Amber E. , Kent Jason , Forquer Isaac , Town Ajia , Klug Lillian R. , McCann Kelly , Beadling Carol , Harismendy Oliver , Sicklick Jason K. , Corless Christopher , Shinde Ujwal , Heinrich Michael C.
Published: April 2023

TIFF file for supplemental figure 1
Supplementary Figure 1 from Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Tetzlaff Michael T. , Curry Jonathan L. , Ning Jing , Sagiv Oded , Kandl Thomas L. , Peng Bo , Bell Diana , Routbort Mark , Hudgens Courtney W. , Ivan Doina , Kim Tae-Boom , Chen Ken , Eterovic Agda Karina , Shaw Kenna , Prieto Victor G. , Yemelyanova Anna , Esmaeli Bita
Published: April 2023

Supplemental Figure 1. Representative images of nuclear grade. Histopathologic grade was defined according to the nuclear morphology and cytoplasmic evidence of sebaceous differentiation comprising the predominance (>50%) of the tumor cells. (A) High grade tumors exhibited enlarged irregular nuclei with high nuclear:cytoplasmic ratio and only focal evidence of sebaceous differentiation (intracytoplasmic vacuoles indenting the nucleus; H&E, 200x). (B) Intermediate grade tumors exhibited similar enlarged nuclei but with lower nuclear:cytoplasmic ratio and more obvious evidence of sebaceous differentiation (H&E, 200x). (C) Well-differentiated tumors showed only slightly enlarged nuclei and frank evidence of sebaceous differentiation (H&E, 200x).
Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Authors: Day Terry A. , Shirai Keisuke , O'Brien Paul E. , Matheus Maria Gisele , Godwin Kristina , Sood Amit J. , Kompelli Anvesh , Vick Julie A. , Martin Daniel , Vitale-Cross Lynn , Callejas-Varela Juan Luis , Wang Zhiyong , Wu Xingyu , Harismendy Olivier , Molinolo Alfredo A. , Lippman Scott M. , Van Waes Carter , Szabo Eva , Gutkind J. Silvio
Published: April 2023

Supplemental Materials and Figures Supplemental Figure 1. Trial design. A single-arm, open-label, interventional, neoadjuvant clinical trial design was used for our study. At the indicated days patients were screened, and laboratory tests, physical exam, CT and PET scans, and tissue biopsies were performed as described in the text. Daily rapamycin was delivered orally for 21 days, with a 15 mg dose on day 1, followed by a 5 mg dose planned for the remaining days. Serum concentrations of rapamycin were measured on dosing days 8 and 15. Definitive treatment (surgery or chemoradiation) was performed after day 28. Patients were followed up for 1 year after definitive treatment.
Supplementary Table 1 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Table 1
Supplementary Data from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Figure Legend
Supplementary Materials and Methods from An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Authors: Piro Geny , Carbone Carmine , Cataldo Ivana , Di Nicolantonio Federica , Giacopuzzi Simone , Aprile Giuseppe , Simionato Francesca , Boschi Federico , Zanotto Marco , Mina Maria Mihaela , Santoro Raffaela , Merz Valeria , Sbarbati Andrea , de Manzoni Giovanni , Scarpa Aldo , Tortora Giampaolo , Melisi Davide
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S3 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Mutation Prevalence at SFU
Supplementary Figure. S2 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Representative CWR22 tumor images of anti-GRM1 immunostaining using two different primary antibodies.
Supplementary Materials and Methods highlighted from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

Supplementary Materials and Methods highlighted
Supplementary Figure S3 from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

Supplementary Figure S3
Table S1 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Authors: Hanker Ariella B. , Garrett Joan T. , Estrada Mónica Valeria , Moore Preston D. , Ericsson Paula González , Koch James P. , Langley Emma , Singh Sharat , Kim Phillip S. , Frampton Garrett M. , Sanford Eric , Owens Philip , Becker Jennifer , Groseclose M. Reid , Castellino Stephen , Joensuu Heikki , Huober Jens , Brase Jan C. , Majjaj Samira , Brohée Sylvain , Venet David , Brown David , Baselga José , Piccart Martine , Sotiriou Christos , Arteaga Carlos L.
Published: April 2023

Table S1. Deep sequencing of ERBB2 does not identify recurrent ERBB2 mutations in LTR tumors.
Supplementary Table S3: Hazard ratios (HR) and confidence intervals (CI) for disease-free survival (DFS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Changes of CTC numbers in the total study cohort or in any of the different subgroups were not related to DFS.
Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer
Authors: Pitroda Sean P. , Bao Riyue , Andrade Jorge , Weichselbaum Ralph R. , Connell Philip P.
Published: April 2023

This file includes: (1) legends for Supplementary Figures S1-S8 and Tables S1-S5 and (2) Supplementary Figures S1-S8. Figure S1: Study flow chart for selection of breast cancer patients. Figure S2: Distributions of SCAN normalized gene expression data. Figure S3: Schematic for development of breast cancer-specific RPS values. Figure S4: Variable importance of clinical, pathologic and gene expression features. Figure S5: RPS values in BRCA-mutated clinical breast cancers. Figure S6: RPS associates with adverse clinical-pathologic features. Figure S7: RPS predicts residual cancer burden following neoadjuvant doxorubicinbased chemotherapy in breast cancer. Figure S8: RPS values as a function of hormone receptor and HER2 in breast cancer.
Table S2 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

Combination index of pictilisib and other drugs in TCCSUP cells
Figure S1 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

Cell cycle analysis, Flow cytometric analysis and p-AKT expression in TCCSUP cells treated with pictilisib
Table S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Authors: Joseph Richard W. , Elassaiss-Schaap Jeroen , Kefford Richard , Hwu Wen-Jen , Wolchok Jedd D. , Joshua Anthony M. , Ribas Antoni , Hodi F. Stephen , Hamid Omid , Robert Caroline , Daud Adil , Dronca Roxana , Hersey Peter , Weber Jeffrey S. , Patnaik Amita , de Alwis Dinesh P. , Perrone Andrea , Zhang Jin , Kang S. Peter , Ebbinghaus Scot , Anderson Keaven M. , Gangadhar Tara C.
Published: April 2023

Supplemental Table
Supplementary Table S1 from Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Authors: Xu Qingyu , Li Yan , Lv Na , Jing Yu , Xu Yihan , Li Yuyan , Li Wenjun , Yao Zilong , Chen Xiaosu , Huang Sai , Wang Lili , Li Yonghui , Yu Li
Published: April 2023

Supplementary Table S1. General statistics of studies included in the meta-analysis.
Supplementary Figure S1-6 from Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Authors: Xu Qingyu , Li Yan , Lv Na , Jing Yu , Xu Yihan , Li Yuyan , Li Wenjun , Yao Zilong , Chen Xiaosu , Huang Sai , Wang Lili , Li Yonghui , Yu Li
Published: April 2023

Supplementary Figure S1. Impact of IDH mutation on survival in CN-AML patients; Supplementary Figure S2. Impact of IDH2 mutation on survival in CN-AML patients; Supplementary Figure S3. Impact of the IDH2 (R140) mutation on survival; Supplementary Figure S4. Impact of the IDH2 (R172) mutation on survival; Supplementary Figure S5. Impact of IDH2 mutations on treatment outcome; Supplementary Figure S6. Funnel plot for the publication bias test of the IDH1/2 mutations in OS.